{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:41:12Z","timestamp":1761100872661,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":3021,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.bbmt.2006.10.010","type":"journal-article","created":{"date-parts":[[2007,1,11]],"date-time":"2007-01-11T07:59:01Z","timestamp":1168502341000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S1","title":["Cancer Stem Cells: From Bench to Bedside"],"prefix":"10.1016","volume":"13","author":[{"given":"Richard J.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2006.10.010_bib1","first-page":"411","article-title":"Mouse myeloma tumor stem cells: a primary cell culture assay","volume":"46","author":"Park","year":"1971","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2006.10.010_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1126\/science.560061","article-title":"Primary bioassay of human tumor stem cells","volume":"197","author":"Hamburger","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2006.10.010_bib3","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.58.4.1468","article-title":"Clonal origin of chronic myelocytic leukemia in man","volume":"58","author":"Fialkow","year":"1967","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2006.10.010_bib4","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood.V81.11.2898.2898","article-title":"BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia","volume":"81","author":"Bedi","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2006.10.010_bib6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood.V87.4.1539.bloodjournal8741539","article-title":"Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis","volume":"87","author":"Sirard","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2001-12-0188","article-title":"Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8","volume":"100","author":"Nilsson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib8","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al Hajj","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2006.10.010_bib9","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib10","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2006.10.010_bib11","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.2036535100","article-title":"Cancerous stem cells can arise from pediatric brain tumors","volume":"100","author":"Hemmati","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2006.10.010_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2005.03.032","article-title":"Identification of bronchioalveolar stem cells in normal lung and lung cancer","volume":"121","author":"Kim","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2006.10.010_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2005-06-2517","article-title":"The paradox of response and survival in cancer therapeutics","volume":"107","author":"Huff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib14","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2006.10.010_bib15","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1200\/JCO.2004.05.111","article-title":"Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials","volume":"22","author":"Durie","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.10.010_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.10.010_bib17","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.10.010_bib18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.10.010_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.md.0000173272.71949.a1","article-title":"A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy","volume":"84","author":"Levy","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbmt.2006.10.010_bib20","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2004.12.082","article-title":"Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate","volume":"22","author":"Rocha Lima","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.10.010_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11934-003-0074-3","article-title":"Chemotherapy of prostate cancer: present and future","volume":"4","author":"Trump","year":"2003","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.bbmt.2006.10.010_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.10.010_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.10.010_bib24","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib25","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib26","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2006.10.010_bib27","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2006.10.010_bib28","first-page":"569","article-title":"Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of BCR-ABL","volume":"22","author":"Mauro","year":"2003","journal-title":"Proc ASCO"},{"key":"10.1016\/j.bbmt.2006.10.010_bib29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2006.10.010_bib30","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2006.10.010_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib32","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors","volume":"130","author":"Angstreich","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2006.10.010_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0301-472X(02)00787-7","article-title":"Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction","volume":"30","author":"Raaijmakers","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2006.10.010_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/stem.200011","article-title":"ABC transporters as phenotypic markers and functional regulators of stem cells","volume":"20","author":"Bunting","year":"2002","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbmt.2006.10.010_bib36","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib37","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.10.010_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4161\/cbt.240","article-title":"Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes","volume":"2","author":"Jiang","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bbmt.2006.10.010_bib40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jnci\/djh095","article-title":"Cancer stem cells: are we missing the target?","volume":"96","author":"Jones","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2006.10.010_bib41","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.thj.6200114","article-title":"The specific enhancement of interferon alpha induced growth inhibition by BCR\/ABL only occurs in multipotent cells","volume":"2","author":"Pierce","year":"2001","journal-title":"Hematol J"},{"key":"10.1016\/j.bbmt.2006.10.010_bib43","doi-asserted-by":"crossref","first-page":"679a","DOI":"10.1182\/blood.V104.11.2476.2476","article-title":"Multiple myeloma stem cells and plasma cells display distinct drug sensitivities","volume":"104","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","article-title":"CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications","volume":"25","author":"Treon","year":"2002","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2006.10.010_bib45","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.leu.2401178","article-title":"In AML t(8;21) colony growth of both leukemic and residual normal progenitors is restricted to the CD34+, lineage-negative fraction","volume":"12","author":"Wittebol","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2006.10.010_bib46","first-page":"3906","article-title":"Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor","volume":"5","author":"Uckun","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2006.10.010_bib47","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/cncr.11219","article-title":"Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311","volume":"97","author":"Szatrowski","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.10.010_bib48","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/sj.leu.2400754","article-title":"Cytogenetically aberrant cells are present in the CD34+CD33-38-19- marrow compartment in children with acute lymphoblastic leukemia","volume":"11","author":"Quijano","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2006.10.010_bib49","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/0008-5472.CAN-04-1356","article-title":"Leukemic stem cells in childhood high-risk ALL\/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+19- cells","volume":"65","author":"Hotfilder","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2006.10.010_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2006.10.010_bib51","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1038\/sj.onc.1207948","article-title":"Does the reservoir for self-renewal stem from the ends?","volume":"23","author":"Harrington","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbmt.2006.10.010_bib52","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2005.11.020","article-title":"Short telomeres, even in the presence of telomerase, limit tissue renewal capacity","volume":"123","author":"Hao","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2006.10.010_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0268-960X(03)00020-1","article-title":"Dyskeratosis congenita: its link to telomerase and aplastic anaemia","volume":"17","author":"Dokal","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2006.10.010_bib54","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0092-8674(00)80761-8","article-title":"Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2\/3) cancer-prone mouse","volume":"97","author":"Greenberg","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2006.10.010_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/88871","article-title":"Telomere dysfunction and evolution of intestinal carcinoma in mice and humans","volume":"28","author":"Rudolph","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.bbmt.2006.10.010_bib56","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/nm1297-1337","article-title":"Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species","volume":"3","author":"Goodell","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2006.10.010_bib57","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","article-title":"Aplastic anaemia","volume":"365","author":"Brodsky","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2006.10.010_bib58","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood.V85.10.2742.bloodjournal85102742","article-title":"Assessment of aldehyde dehydrogenase in viable cells","volume":"85","author":"Jones","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.10.010_bib59","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1634\/stemcells.2005-0217","article-title":"Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity","volume":"24","author":"Corti","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbmt.2006.10.010_bib60","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.0400067101","article-title":"A distinct \u201cside population\u201d of cells with high drug efflux capacity in human tumor cells","volume":"101","author":"Hirschmann-Jax","year":"2004","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106007130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:29:33Z","timestamp":1761056973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879106007130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":60,"alternative-id":["S1083879106007130"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.10.010","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer Stem Cells: From Bench to Bedside","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}